Skip to main content

Research News

academics

 

Clinical research courses

  • IISc start-up gets regulatory approvals for COVID-19 test

    PathShodh Healthcare, a start-up incubated at the Society for Innovation and Development (SID), Indian Institute of Science (IISc), has made a significant breakthrough in developing a first-of-its-kind, semi-quantitative electrochemical ELISA test for COVID-19 IgM and IgG antibodies.

  • Tulane researchers develop test that detects childhood TB a year ahead of current screenings

    Researchers at Tulane University School of Medicine have developed a highly sensitive blood test that can find traces of the bacteria that causes tuberculosis (TB) in infants a year before they develop the deadly disease, according to a study published in BMC Medicine.

  • Machine learning (AI) accurately predicts cardiac arrest risk

    A branch of artificial intelligence (AI), called machine learning, can accurately predict the risk of an out of hospital cardiac arrest when the heart suddenly stops beating using a combination of timing and weather data, finds research published online in the journal Heart.

    Machine learning is the study of computer algorithms, and based on the idea that systems can learn from data and identify patterns to inform decisions with minimal intervention.

  • Insulin is necessary for repairing olfactory neurons

    Researchers have known for some time that insulin plays a vital role in regeneration and growth in some types of neurons that relay environmental sensory information to our brains, such as sight.

  • Clopidogrel Superior to Aspirin for Long Term Post Stent Maintenance

    Patients saw 30 percent reduced risk of adverse events after two years of follow up. Clopidogrel outperformed aspirin in what is believed to be the first and largest randomized trial to compare the effectiveness of the two antiplatelet drugs as long term maintenance therapy for patients who had no adverse events after one year of dual antiplatelet therapy following the insertion of a coronary stent.

  • DCGI approves 2-DG medicine for moderate to severe COVID-19 cases

    The Drugs Controller General of India, DCGI, has given permission for the emergency use of 2 deoxyD-glucose, 2-DG medicine as an adjunct therapy in moderate to severe Covid-19 cases.

    An anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy’s Laboratories (DRL), Hyderabad.

  • Alligators mitazalimab shown to enhance cancer vaccine

    Alligator Bioscience announced that preclinical data on its agonist anti-CD40 antibody mitazalimab has been published in the scientific journal Cancer Immunology, Immunotherapy.

    The published data show that mitazalimab activates dendritic cells and tumor-reactive T cells resulting in enhanced anti-tumor efficacy in combination with a model cancer vaccine.

  • Gene therapy in alzheimers disease mouse model preserves learning and memory

    Researchers at University of California San Diego School of Medicine, with colleagues elsewhere, have used gene therapy to prevent learning and memory loss in a mouse model of Alzheimers disease, a key step toward eventually testing the approach in humans with the neurodegenerative disease. The findings are published online in advance of the June 11, 2021 issue of Molecular Therapy-Methods & Clinical Development. 

  • AYUSH 64 found useful in the treatment of mild to moderate COVID-19 infection

    In the middle of the havoc wreaked by second wave of the pandemic, AYUSH-64 has emerged as a ray of hope for the patients of mild and moderate COVID-19 infection. The scientists of reputed research institutions of the country have found that AYUSH 64, a poly herbal formulation developed by the Central Council for Research in Ayurvedic Sciences (CCRAS), Ministry of Ayush is useful in the treatment of asymptomatic, mild and moderate COVID-19 infection as an adjunct to standard care.

  • New test detects residual cancer DNA in the blood without relying on tumor data

    After patients with cancer undergo surgery to remove a tumor and sometimes additional chemotherapy, tools are used to identify patients at highest risk of recurrence. Non-invasive tools to detect microscopic disease are of especially high value. In a new study published in Clinical Cancer Research, a team led by investigators at Massachusetts General Hospital (MGH) has evaluated the first tumor-uninformed test that detects cancer DNA circulating in the blood of patients following treatment.

Subscribe to Research News